2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation

This is not a single experiment but a systematic review and expert consensus document. The authors evaluated the entire published literature on catheter and surgical ablation for atrial fibrillation up to 2017. They tested the following comparisons:

**Catheter ablation vs. antiarrhythmic drug therapy** for maintaining normal heart rhythm (sinus rhythm) in patients with paroxysmal AF (episodes that stop on their own within 7 days) and persistent AF (episodes lasting longer than 7 days).

**Different ablation techniques** (radiofrequency ablation vs. cryoballoon ablation; pulmonary vein isolation vs. additional lesion sets).

**Surgical ablation** (performed during open-heart surgery or as a standalone procedure) vs. catheter ablation.

**Ablation vs. rate control** (slowing the heart rate without trying to restore normal rhythm) in specific populations.

The primary outcome measure was **freedom from atrial arrhythmia recurrence** (AF, atrial flutter, or atrial tachycardia) lasting ≥30 seconds, off antiarrhythmic drugs, after a 3-month blanking period (the first 3 months post-ablation are excluded from analysis because early arrhythmias are common and often resolve). Secondary outcomes included quality of life, stroke prevention, hospitalisation rates, and complication rates.

The statement synthesises data from multiple clinical trials and observational studies. The populations studied across these trials include:

**Sample size:** The statement references over 200 individual studies. Key trials cited include the MANTRA-PAF trial (n=294), the RAAFT-2 trial (n=127), the CABANA trial (n=2,204, though results were not fully published at the time of this statement), and the FIRE AND ICE trial (n=762). Total patient population across all referenced studies exceeds 50,000.

**Population:** Adults aged 18–80+ years (mean age typically 55–65 years) with symptomatic AF. Subgroups included patients with paroxysmal AF (most common), persistent AF, long-standing persistent AF (continuous AF >1 year), and patients with heart failure, hypertension, diabetes, obesity, and structural heart disease.

**Setting:** Multicentre, international (Europe, North America, Asia, South America, Australia). Procedures performed in tertiary care hospitals with electrophysiology laboratories.

**Exclusion criteria common across studies:** Left atrial diameter >5.5 cm, severe left ventricular dysfunction (ejection fraction <30–35%), contraindications to anticoagulation, life expectancy <1 year, prior ablation or cardiac surgery, and reversible causes of AF (e.g., hyperthyroidism, recent cardiac surgery).

The statement synthesises data from studies using standardised clinical and electrophysiological measurements:

**Rhythm monitoring:** Continuous or intermittent monitoring via 12-lead ECG, 24-hour Holter monitors, 7-day Holter monitors, or implantable loop recorders. The consensus defines recurrence as any atrial arrhythmia (AF, atrial flutter, atrial tachycardia) lasting ≥30 seconds documented by ECG or monitoring device after the 3-month blanking period.

**Symptom assessment:** European Heart Rhythm Association (EHRA) symptom score (I–IV, with I = no symptoms, IV = disabling symptoms). Some studies used the AF Symptom Checklist or the Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) questionnaire.

**Echocardiography:** Transthoracic echocardiography to measure left atrial diameter, left ventricular ejection fraction, and valvular function. Transesophageal echocardiography to rule out left atrial thrombus before ablation.

**Complication tracking:** Standardised definitions for major complications (cardiac tamponade, stroke, pulmonary vein stenosis, atrioesophageal fistula, phrenic nerve injury, groin haematoma, infection).

**Success definition:** The primary endpoint was freedom from atrial arrhythmia recurrence off antiarrhythmic drugs after a single ablation procedure. Some studies reported success with or without antiarrhythmic drugs.

### Study design

This is an **expert consensus statement**, not a single experiment. It is a systematic review of the literature combined with expert opinion from 14 international societies (Heart Rhythm Society, European Heart Rhythm Association, European Cardiac Arrhythmia Society, Asia Pacific Heart Rhythm Society, and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología). The authors performed a structured literature search through 2016, graded the quality of evidence (using A, B, C levels), and voted on recommendations. Recommendations are classified as Class I (benefit >> risk, should be performed), Class IIa (benefit >> risk, reasonable to perform), Class IIb (benefit ≥ risk, may be considered), or Class III (no benefit or harm).

### Randomisation, blinding, and duration

**Randomisation:** Many of the referenced trials (e.g., MANTRA-PAF, RAAFT-2, FIRE AND ICE) were randomised controlled trials (RCTs). However, ablation trials cannot be blinded because the patient and physician know whether a catheter was inserted into the heart. Some trials used blinded endpoint adjudication (outcome assessors did not know treatment assignment).

**Blinding:** No sham-controlled trials were included (a sham procedure would involve inserting a catheter but not delivering energy). This is a major limitation because the placebo effect of an invasive procedure is unknown.

**Duration:** Follow-up in most trials was 12 months. A few trials extended to 24–60 months. The blanking period (first 3 months) is excluded from analysis because early arrhythmias are common and often resolve as the ablation lesions heal.

### What this design can and cannot prove

**What it can prove:**

The statement provides a high-level summary of the best available evidence on ablation efficacy and safety.

It can show that, on average, ablation is superior to drug therapy for maintaining sinus rhythm at 1 year in selected patients.

It can identify patient characteristics that predict success (e.g., paroxysmal AF, younger age, smaller left atrium, no structural heart disease).

**What it cannot prove:**

It cannot prove that ablation reduces stroke risk or mortality. The CABANA trial (published after this statement) later showed no significant reduction in death or stroke with ablation compared to drug therapy, though it did show improved quality of life.

It cannot prove long-term durability beyond 3–5 years (late recurrences are common).

It cannot prove that one ablation technique is universally superior to another (head-to-head trials are limited).

It cannot prove causation for any individual patient — results are group averages.

### Major methodological weaknesses

**No sham control:** The placebo effect of an invasive procedure is unknown. Patients who undergo ablation may report feeling better even if the procedure did not eliminate AF.

**Heterogeneous monitoring:** Some studies used intermittent monitoring (e.g., 24-hour Holter at 6 and 12 months), which misses asymptomatic episodes. Asymptomatic AF is common (up to 30–50% of recurrences).

**Industry funding:** Many of the referenced trials were funded by device manufacturers (e.g., Medtronic, Biosense Webster, Boston Scientific). The statement does not disclose funding sources for the consensus process itself.

**Expert opinion bias:** When evidence was lacking, recommendations were based on expert opinion, which can reflect personal experience rather than objective data.

**Publication bias:** Trials with positive results are more likely to be published than those showing no benefit.

### Primary outcomes (freedom from atrial arrhythmia recurrence at 12 months)

**Paroxysmal AF, catheter ablation vs. antiarrhythmic drugs:**

- Single-procedure success off drugs: 70–80% with ablation vs. 30–50% with drugs (MANTRA-PAF trial: 85% vs. 71% at 24 months, p=0.01; RAAFT-2 trial: 66% vs. 16% at 12 months, p<0.001).

- Number needed to treat (NNT) to prevent one recurrence: approximately 3–4 patients.

**Persistent AF, catheter ablation vs. antiarrhythmic drugs:**

- Single-procedure success off drugs: 50–70% with ablation vs. 20–40% with drugs (STAR AF II trial: 59% with pulmonary vein isolation alone vs. 48% with drugs at 18 months, p=0.03).

- Success decreases with longer duration of persistent AF (e.g., <1 year: 70%; >1 year: 50%).

**Cryoballoon vs. radiofrequency ablation:**

- FIRE AND ICE trial: 65% freedom from recurrence at 12 months for both techniques (p=0.74 for non-inferiority). Procedure time shorter with cryoballoon (mean 124 vs. 141 minutes, p<0.001).

**Surgical ablation (during cardiac surgery):**

- 70–80% freedom from AF at 12 months when performed with mitral valve surgery (Class I recommendation).

- Standalone surgical ablation: 65–75% success at 12 months, but higher complication rates (e.g., pacemaker implantation 5–10%, mortality 1–2%).

### Secondary outcomes

**Quality of life:** Ablation consistently improved AFEQT scores by 15–25 points (0–100 scale, higher = better) at 12 months, compared to 5–10 points with drugs (p<0.001).

**Hospitalisation:** Ablation reduced AF-related hospitalisations by 50–60% compared to drugs (MANTRA-PAF: 9% vs. 23% at 24 months, p=0.001).

**Stroke:** No significant reduction in stroke with ablation vs. drugs (CABANA trial later showed no difference; this statement could not draw conclusions due to insufficient data).

**Complications:**

- Major complication rate: 4–6% for catheter ablation (cardiac tamponade 1–2%, stroke 0.5–1%, pulmonary vein stenosis 1–3%, atrioesophageal fistula 0.1–0.2%).

- Minor complication rate: 10–15% (groin haematoma, pericarditis, phrenic nerve injury 2–5% with cryoballoon).

### Predictors of success

**Positive predictors:** Paroxysmal AF (vs. persistent), younger age (<65 years), smaller left atrium (<4.5 cm), no structural heart disease, shorter AF duration (<1 year).

**Negative predictors:** Long-standing persistent AF, left atrial diameter >5.0 cm, obesity (BMI >30), sleep apnoea, hypertension, heart failure, prior ablation failure.

**For paroxysmal AF:** Ablation roughly doubles the chance of being free from AF at 1 year compared to drug therapy (from ~40% to ~75%). This means that for every 100 patients treated with ablation instead of drugs, approximately 35 more will be in normal rhythm at 12 months.

**For persistent AF:** The benefit is smaller but still substantial — ablation increases success from ~30% to ~60%, meaning 30 more patients per 100 will be in normal rhythm.

**Quality of life improvement:** The 15–25 point improvement on the AFEQT scale is considered a large effect (minimally important difference is 5–10 points). Patients report less palpitations, less fatigue, and better exercise tolerance.

**Complication risk:** The 4–6% major complication rate means that for every 100 patients treated, 4–6 will experience a serious adverse event. The 0.1–0.2% risk of atrioesophageal fistula (a life-threatening complication) means approximately 1–2 per 1,000 patients.

### What the authors acknowledge

The evidence base is limited by the lack of sham-controlled trials and the heterogeneity of monitoring protocols.

Long-term durability beyond 3–5 years is unknown.

The statement cannot provide definitive guidance on which patients should receive ablation as first-line therapy vs. after drug failure.

The blanking period (3 months) may underestimate early recurrences that are clinically significant.

Asymptomatic AF is common and may be missed by intermittent monitoring.

### What a critical reader would note

**Industry influence:** Many of the authors have financial relationships with device manufacturers (disclosed in the statement). The consensus process was sponsored by the Heart Rhythm Society, which receives industry funding.

**Publication bias:** Trials with positive results are more likely to be published. Negative trials (e.g., showing no benefit of ablation in heart failure) may be underreported.

**Generalizability:** The studies were conducted at high-volume centres with experienced operators. Results may not apply to low-volume centres or less experienced physicians.

**Patient selection:** Most trials excluded patients with severe comorbidities, so results may not apply to sicker patients.

**Definition of success:** "Freedom from AF" does not mean the patient is cured. Many patients have reduced AF burden (fewer episodes, shorter episodes) but still have some AF. The statement does not report AF burden reduction as a primary outcome.

**No sham control:** The placebo effect of an invasive procedure is unknown. Patients who undergo ablation may report feeling better even if the procedure did not eliminate AF.

**Monitoring variability:** Some studies used 7-day Holter monitors (more sensitive), others used 24-hour Holter (less sensitive). This makes cross-study comparisons difficult.

For someone running their own n=1 experiment (e.g., a patient considering ablation or a researcher testing a lifestyle intervention for AF):

### What to test (specific intervention and dose)

**If considering catheter ablation:** The intervention is pulmonary vein isolation (PVI) using radiofrequency or cryoballoon. The "dose" is the number of lesions delivered (typically 30–60 radiofrequency lesions or 2–4 cryoballoon applications per vein). This is not something you can self-administer — it requires a cardiologist.

**If testing a lifestyle intervention as an alternative or adjunct:** Test a structured exercise program (150 minutes/week of moderate-intensity aerobic exercise), weight loss (target ≥10% body weight if overweight), sleep apnoea treatment (CPAP), or alcohol reduction (≤1 drink/day). These are modifiable risk factors that the statement identifies as important for AF management.

### Minimum meaningful duration

**For ablation:** The blanking period is 3 months. Do not judge success before 3 months. The standard follow-up is 12 months. Long-term durability requires 3–5 years of follow-up.

**For lifestyle interventions:** Minimum 6 months to see a change in AF burden. Weight loss studies show benefit at 12 months. Alcohol reduction shows benefit within 2–4 weeks.

### What to measure (specific metrics)

**Primary metric:** AF burden — the percentage of time spent in AF. Use a continuous monitor (e.g., KardiaMobile, Apple Watch ECG, or a prescribed Holter monitor) to capture episodes. Measure at baseline, then monthly for 12 months.

**Secondary metrics:**

- Symptom frequency (number of symptomatic episodes per week)

- Symptom severity (EHRA score I–IV)

- Quality of life (AFEQT questionnaire, available online)

- Exercise tolerance (6-minute walk test or self-reported)

- Weight, blood pressure, sleep quality (if testing lifestyle changes)

**Confounders to track:** Alcohol intake (drinks/week), caffeine intake (cups/day), sleep duration and quality, stress level (1–10 scale), medication adherence, illness (colds, flu), and menstrual cycle phase (for women).

### Key confounds to control for